Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

hormone-sensitive cancers

  • Home
  • hormone-sensitive cancers
GLP-1 Receptor Agonists in Obesity: Emerging Evidence for Cancer Risk Modulation
Posted inClinical Updates news

GLP-1 Receptor Agonists in Obesity: Emerging Evidence for Cancer Risk Modulation

Posted by MedXY By MedXY 08/31/2025
GLP-1 receptor agonists, used for obesity and type 2 diabetes management, are linked to a 17% lower overall cancer risk, notably hormone-sensitive cancers, but may increase kidney cancer risk. Further research is needed to clarify safety and mechanisms.
Read More
  • Pre-diagnostic Clonal Hematopoiesis Raises Risk of Second Cancers in Patients With Primary Cancer
  • Targeting Post-Transplant Myeloid Immune Suppression in Multiple Myeloma: Why CSF-1R Blockade May Enhance Lenalidomide Maintenance After ASCT
  • Bronchoscopy in Germany Generates More Than 550 Tons of Waste Annually, With Reusable PPE Offering the Largest Immediate Reduction
  • Quantitative CT Progression Thresholds in Idiopathic Pulmonary Fibrosis May Sharpen Annual Monitoring and Risk Stratification
  • Subclinical Peripheral Vascular Leakage in Demyelinating Disease-Associated Uveitis: What Ultra-Widefield Angiography Adds Beyond Clinical Quiescence
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in